Gender differences in cancer patients with acute venous thromboembolism

ABSTRACT Background: The outcome of cancer patients with acute venous thromboembolism (VTE) may differ according to gender. Methods: We used the RIETE database to compare the rate of VTE (pulmonary embolism [PE] or deep vein thrombosis [DVT]) recurrences), major bleeding and mortality during the cou...

Full description

Saved in:
Bibliographic Details
Published inThrombosis research Vol. 135; pp. S12 - S15
Main Authors Martín-Martos, Francisco, Trujillo-Santos, Javier, Barrón, Manuel, Vela, Jerónimo, Javier Marchena, Pablo, Braester, Andrei, Hij, Adrian, Hernández-Blasco, Luis, Verhamme, Peter, Manuel, Monreal, RIETE Investigators
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 01.02.2015
Elsevier
Subjects
Acute Disease
Aged
Anticoagulant drugs
Anticoagulants - therapeutic use
Cancer
Comorbidity
Female
Gender
Hematology
Hematology, Oncology and Palliative Medicine
Hemorrhage
Hemorrhage - mortality
Human health and pathology
Humans
Incidence
Life Sciences
Male
Mortality
Neoplasms - mortality
Recurrence
Risk Factors
Sex Characteristics
Sex Distribution
Spain - epidemiology
Survival Rate
Treatment Outcome
Venous thromboembolism
Venous Thromboembolism - drug therapy
Venous Thromboembolism - mortality
Spain
Recurrence
Mortality
Anticoagulant drugs
Gender
Hemorrhage
Venous thromboembolism
Cancer
Online AccessGet full text

Cover

More Information
Summary:ABSTRACT Background: The outcome of cancer patients with acute venous thromboembolism (VTE) may differ according to gender. Methods: We used the RIETE database to compare the rate of VTE (pulmonary embolism [PE] or deep vein thrombosis [DVT]) recurrences), major bleeding and mortality during the course of anticoagulation, according to gender. Results: As of August 2014, 11,055 patients with active cancer were enrolled in RIETE, of whom 5,104 (46%) were women. During the course of anticoagulation (mean: 142 days), 505 patients developed recurrent VTE, 429 bled and 2730 died. Compared with men, women had a significantly lower rate of fatal bleeding (risk ratio [RR]: 0.69; 95% CI: 0.47–0.99) and death (RR: 0.90; 95% CI: 0.83–0.97), and a non-significantly lower rate of PE recurrences (RR 0.83; 95% CI: 0.65–1.06) and major bleeding (RR: 0.89; 95% CI: 0.74–1.08). Conclusions: During the course of anticoagulation, cancer women with VTE had a better outcome than men.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0049-3848
1879-2472
DOI:10.1016/S0049-3848(15)50433-7